Middle East Respiratory Syndrome (MERS) – Pipeline Review, H2 2019

Global Markets Direct’s, ‘Middle East Respiratory Syndrome (MERS) – Pipeline Review, H2 2019’, provides an overview of the Middle East Respiratory Syndrome (MERS) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Middle East Respiratory Syndrome (MERS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Middle East Respiratory Syndrome (MERS) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Middle East Respiratory Syndrome (MERS)

The report reviews pipeline therapeutics for Middle East Respiratory Syndrome (MERS) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Middle East Respiratory Syndrome (MERS) therapeutics and enlists all their major and minor projects

The report assesses Middle East Respiratory Syndrome (MERS) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Middle East Respiratory Syndrome (MERS)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Middle East Respiratory Syndrome (MERS)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Middle East Respiratory Syndrome (MERS) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abhelix LLC

Anglo Biopharma Ltd

Atriva Therapeutics GmbH

Autoimmune Technologies LLC

Future Medicine Co Ltd

Gilead Sciences Inc

Global BioLife Inc Ltd

Greffex Inc

Humabs BioMed SA

Inovio Pharmaceuticals Inc

NanoViricides Inc

Novavax Inc

Phelix Therapeutics LLC

Regeneron Pharmaceuticals Inc

Romark Laboratories LC

SAB Biotherapeutics Inc

Signia Therapeutics

Sumagen Co Ltd

Themis Bioscience GmbH

Vaccitech Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Middle East Respiratory Syndrome (MERS) Overview

Middle East Respiratory Syndrome (MERS) Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Middle East Respiratory Syndrome (MERS) Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Middle East Respiratory Syndrome (MERS) Companies Involved in Therapeutics Development

Autoimmune Technologies LLC

Gilead Sciences Inc

Inovio Pharmaceuticals Inc

Kineta Inc

NanoViricides Inc

Novavax Inc

Phelix Therapeutics LLC

Regeneron Pharmaceuticals Inc

Romark Laboratories LC

Themis Bioscience GmbH

Vaccitech Ltd

Middle East Respiratory Syndrome (MERS) Drug Profiles

3B-11 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BNSP-333S1 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CSW-1 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Middle East Respiratory Syndrome Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Inhibit Cathepsin L for Coronaviridae Infections Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FM-2101 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GreMERSfi Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INO-4301 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KIN-1400 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LB-2 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LCA-60 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Middle East respiratory syndrome coronavirus vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Middle East respiratory syndrome vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Middle East respiratory syndrome vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Middle East respiratory syndrome vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Middle East respiratory syndrome vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies for Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nitazoxanide Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REGN-3048 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REGN-3051 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

remdesivir Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAB-301 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Middle East Respiratory Syndrome Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Middle East Respiratory Syndrome (MERS) Dormant Projects

Middle East Respiratory Syndrome (MERS) Product Development Milestones

Featured News & Press Releases

Jan 10, 2018: First Treatment for MERS Appears Safe in NIH Phase I Clinical Trial

Sep 18, 2017: Inovio and Partners Initiate Phase 1/2a Clinical Trial To Further Advance Its Vaccine Against Deadly MERS Infection

Feb 23, 2017: Inovio Reports New Positive Clinical Data on MERS Vaccine GLS-5300

Dec 06, 2016: Inovio MERS Vaccine Development to be Expanded with Funding from International Vaccine Institute

Aug 24, 2016: SAB Biotherapeutics Announces Contract with BARDA to Advance First MERS Treatment

Aug 11, 2016: Phase I Clinical Trials Underway for First MERS Treatment

Jun 04, 2015: Kineta’s Novel Broad Spectrum Antivirals Trigger Effective Natural Immune Response to Flu and Respiratory Virus Infections

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Middle East Respiratory Syndrome (MERS), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Middle East Respiratory Syndrome (MERS) – Pipeline by Abhelix LLC, H2 2019

Middle East Respiratory Syndrome (MERS) – Pipeline by Anglo Biopharma Ltd, H2 2019

Middle East Respiratory Syndrome (MERS) – Pipeline by Atriva Therapeutics GmbH, H2 2019

Middle East Respiratory Syndrome (MERS) – Pipeline by Autoimmune Technologies LLC, H2 2019

Middle East Respiratory Syndrome (MERS) – Pipeline by Future Medicine Co Ltd, H2 2019

Middle East Respiratory Syndrome (MERS) – Pipeline by Gilead Sciences Inc, H2 2019

Middle East Respiratory Syndrome (MERS) – Pipeline by Global BioLife Inc Ltd, H2 2019

Middle East Respiratory Syndrome (MERS) – Pipeline by Greffex Inc, H2 2019

Middle East Respiratory Syndrome (MERS) – Pipeline by Humabs BioMed SA, H2 2019

Middle East Respiratory Syndrome (MERS) – Pipeline by Inovio Pharmaceuticals Inc, H2 2019

Middle East Respiratory Syndrome (MERS) – Pipeline by NanoViricides Inc, H2 2019

Middle East Respiratory Syndrome (MERS) – Pipeline by Novavax Inc, H2 2019

Middle East Respiratory Syndrome (MERS) – Pipeline by Phelix Therapeutics LLC, H2 2019

Middle East Respiratory Syndrome (MERS) – Pipeline by Regeneron Pharmaceuticals Inc, H2 2019

Middle East Respiratory Syndrome (MERS) – Pipeline by Romark Laboratories LC, H2 2019

Middle East Respiratory Syndrome (MERS) – Pipeline by SAB Biotherapeutics Inc, H2 2019

Middle East Respiratory Syndrome (MERS) – Pipeline by Signia Therapeutics, H2 2019

Middle East Respiratory Syndrome (MERS) – Pipeline by Sumagen Co Ltd, H2 2019

Middle East Respiratory Syndrome (MERS) – Pipeline by Themis Bioscience GmbH, H2 2019

Middle East Respiratory Syndrome (MERS) – Pipeline by Vaccitech Ltd, H2 2019

Middle East Respiratory Syndrome (MERS) – Dormant Projects, H2 2019

List of Figures

List of Figures

Number of Products under Development for Middle East Respiratory Syndrome (MERS), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by Targets, H2 2019

Number of Products by Stage and Targets, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports